Effects of Mirtogenol® on ocular blood flow and intraocular hypertension in asymptomatic subjects

Molecular Vision

Volumn 14, Issue , 2008, Pages 1288-1292

  Steigerwalt Jr , Robert D ^a   Gianni, Belcaro ^a   Paolo, Morazzoni ^b   Bombardelli, Ezio ^b   Burki, Carolina ^c   Schönlau, Frank ^d  

^a UNIVERSITY OF CHIETI   (Italy)

^b INDENA S P A   (Italy)

^c Horphag Research   (Switzerland)

^d Horphag Research UK Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BILBERRY EXTRACT; FLAVONOID; MIRTOGENOL; MIRTOSELECT; PLANT EXTRACT; PYCNOGENOL;

ADULT; ARTICLE; BILBERRY; CILIARY ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ACTIVITY; DRUG EFFICACY; EVENING DOSAGE; EYE BLOOD FLOW; EYE PROTECTION; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; MALE; MEDICINAL PLANT; MORNING DOSAGE; OPHTHALMIC ARTERY; PRIORITY JOURNAL; RETINA ARTERY; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; BLOOD FLOW; DRUG EFFECT; EYE; VASCULARIZATION;

ADULT; EYE; FEMALE; FLAVONOIDS; HUMANS; MALE; OCULAR HYPERTENSION; OPHTHALMIC ARTERY; REGIONAL BLOOD FLOW;

EID: 48949116526     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Rosenthal BP. Ophthalmology: Screening and treatment of age-related and pathologic vision changes. Geriatrics 2001; 56:27-31.
2. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363:1711-20.
3. Christen WG, Liu S, Glynn RJ, Gaziano JM, Buring JE. Dietary carotenoids, vitamins C and E, and risk of cataract in women: a prospective study. Arch Ophthalmol 2008; 126:102-29.
4. Coleman H, Chew E. Nutritional supplementation in age-related macular degeneration. Curr Opin Ophthalmol 2007; 18:220-3.
5. Hodge WG, Schachter HM, Barnes D, Pan Y, Lowcock EC, Zhang L, Sampson M, Morrison A, Tran K, Miguelez M, Lewin G. Efficacy of omega-3 fatty acids in preventing age-related macular degeneration: a systematic review. Ophthalmology 2006; 113:1165-72.
6. Wilkinson-Berka JL, Miller AG. Update on the treatment of diabetic retinopathy. ScientificWorldJournal 2008; 8:98-120.
7. Perossini M, Guidi G, Chiellini S, Siravo D. Diabetic and hypertensive retinopathy therapy with Vaccinium myrtillus anthocyanosides (Tegens). A double blind placebo-controlled clinical trial. Ann Ottalmol Clin Ocul 1987; 113:1173-90.
8. Repossi P, Malagola R, De Cadilhac C. The role of anthocyanosides on vascular permeability in diabetic retinopathy. Ann Ottalmol Clin Ocul 1987; 113:357-61.
9. Schönlau F, Rohdewald P. Pycnogenol for diabetic retinopathy. A review. Int Ophthalmol 2002; 24:161-71.
10. Kang JH, Pasquale LF, Willett W, Rosner B, Egan KM, Faberowski N, Hankinson SE. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am J Epidemiol 2003; 158:337-46.
11. Coleman AL, Stone KL, Kodjebacheva G, Yu F, Pedula KL, Ensrud KE, Cauley JA, Hochberg MC, Topouzis F, Badala F, Mangione CM. Study of osteoporotic fractures research group. Glaucoma Risk and the Consumption of Fruits and Vegetables Among Older Women in the Study of Osteoporotic Fractures. Am J Ophthalmol 2008; 145:1081-9.
12. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK 2nd, Wilson MR, Gordon MO. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120:701-13.
13. Steigerwalt RD Jr, Laurora G, Belcaro GV, Cesarone MR, De Sanctis MT, Incandela L, Minicucci R. Ocular and retrobulbar blood flow in ocular hypertensives treated with topical timolol, betaxolol and carteolol. J Ocul Pharmacol Ther 2001; 17:537-44.
14. Allingham RR, Shields MB. Shields'textbook of glaucoma. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
15. Baudouin C, Liang H, Hamard P, Riancho L, Creuzot-Garcher C, Warnet JM, Brignole-Baudouin F. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology 2008; 115:109-15.
16. Airaksinen PJ, Alanko HI. Vascular effects of timolol and pilocarpine in the iris. A simultaneous bilateral fluorescein angiographic study. Acta Ophthalmol (Copenh) 1983; 61:195-205.
17. Diggory P, Diggory P, Franks WA. Glaucoma therapy may take your breath away. Age Ageing 1997; 26:63-7.
18. Tsai JC. Influencing ocular blood flow in glaucoma patients: the cardiovascular system and healthy lifestyle choices. Can J Ophthalmol 2008; 43:347-50.
19. Liu JH, Kripke DF, Twa MD, Hoffman RE, Mansberger SL, Rex KM, Girkin CA, Weinreb RN. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999; 40:2912-7.
20. Virno M, Pecori Giraldi J, Auriemma L. Antocianosidi di mirtillo e permeabilità dei vasi del corpo ciliare. Boll Ocul 1986; 65:789-95.
21. Galvano F, La Fauci L, Vitaglione P, Fogliano V, Vanella L, Felgines C. Bioavailability, antioxidant and biological properties of the natural free-radical scavengers cyanidin and related glycosides. Ann Ist Super Sanita 2007; 43:382-93.
22. Morazzoni P, Bombardelli E. Vaccinium myrtillus L. Fitoterapia 1996; 67:3-29.
23. Orsucci PL, Rossi M, Sabbatini G, Menci S, Berni M. Trattamento della retinopatia diabetica con antocianosidi. Indagine preliminare. Clin Ocul 1983; 4:77-81.
24. Caselli L. Clinic, electroretinographic trial on the action of anthocyanosides. Arch Med Interna 1985; 37:29-35.
25. Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol®), a herbal medication with a diverse pharmacology. Int J Clin Pharmacol Ther 2002; 40:158-68.
26. Cellini M, Versura P, Zamparini E, Bendo E, Campos EC. Effects of endothelin-1 and flunarizine on human trabecular meshwork cell contraction. Exp Biol Med (Maywood) 2006; 231:1081-4.
27. Schmetterer L, Krejcy K, Kastner J, Wolzt M, Gouya G, Findl O, Lexer F, Breiteneder H, Fercher AF, Eichler HG. The effect of systemic nitric oxide-synthase inhibition on ocular fundus pulsations in man. Exp Eye Res 1997; 64:305-12.
28. Nishioka K, Hidaka T, Nakamura S, Umemura T, Jitsuiki D, Soga J, Goto C, Chayama K, Yoshizumi M, Higashi Y. Pycnogenol, French maritime pine bark extract; augments endothelium-dependent vasodilation in humans. Hypertens Res 2007; 30:775-80.
29. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. Antidiabetic Effect of Pycnogenol® French Maritime Pine Bark Extract in patients with diabetes type II. Life Sci 2004; 75:2505-13.
30. Colantuoni A, Bertuglia S, Magistretti MJ, Donato L. Effects of Vaccinium Myrtillus anthocyanosides on arterial vasomotion. Arzneimittelforschung 1991; 41:905-9.
31. Vetrugno M, Sisto D, Trabucco T, Balducci F, Delle Noci N, Sborgia C. Water-drinking test in patients with primary open-angle glaucoma while treated with different topical medications. J Ocul Pharmacol Ther 2005; 21:250-7.